T reatment-emergent central sleep apnea (TECSA) is characterized by the emergence or persistence of central apneas while undergoing treatment for obstructive sleep apnea (OSA) such as while using positive airway pressure (PAP) therapy.
[1] TECSA typically occurs following substantial resolution of previously witnessed obstructive respiratory events that were identified on a prior diagnostic sleep study or diagnostic portion of a split-night sleep study.
[1] Previous studies have noted that the prevalence of TECSA varies between 3.5% and 20%. [2] [3] [4] [5] [6] [7] [8] [9] [10] A recent systematic review on the prevalence of TECSA found that the aggregate point prevalence of TECSA is around 8% while the estimated range varies from 5% to 20% in patients with untreated OSA. [11] It has been postulated that in a patient with ventilatory instability, continuous positive airway pressure (CPAP) therapy can intermittently lower the partial pressure of arterial carbon dioxide (PaCO 2 ) below the apneic threshold leading to the development of central apneas and this serves as a possible explanation for TECSA. [12] This happens more commonly during nonrapid eye movement sleep when the CO 2 reserve (the difference between eupneic PaCO 2 and the apneic threshold) is highly labile. [12] Most of the patients with TECSA show gradual resolution of central apneas over weeks to months. However, some patients appear to experience central apneas for protracted periods of time. For these patients, CPAP use may be associated with dyspnea or air hunger as well as inadvertent CPAP mask removal during the night. [13] All this can lead to persistence or worsening of sleep-disordered breathing as well as poor sleep quality at night. To the best of our knowledge, the natural history of TECSA has not been evaluated with a systematic review. We would like to delineate any characteristics of a patient population exhibiting central sleep apnea over a protracted period after the initial PAP titration study (i.e., patients with treatment persistent central sleep apnea [TPCSA] ). Therefore, the primary objective of this study was to identify patients with TECSA who continue to experience PAP treatment-related central apneas, weeks to months after initiating CPAP therapy (i.e., patients with persistent refractory central sleep apnea or TPCSA). Secondary objectives included (1) the prevalence of TPCSA if such patients do exist, (2) factors that determine the prevalence of TPCSA, and (3) patients who may exhibit delayed-TECSA (D-TECSA).
Methods
For purposes of clarification, we used the following terminologies:
PAP-1: First PAP treatment data (titration or titration portion of the split-night study or PAP device data for the first time period) that were used to determine the prevalence of TECSA. PAP-2: Second PAP treatment data (titration or the in-lab CPAP study at patient's "home" CPAP setting or PAP device data for the second time period) done weeks to months after PAP-1 on patients with TECSA that were used to determine the prevalence of TPCSA. Alternatively, PAP-2 treatment data could also be used to evaluate for D-TECSA. Extensive grey literature and Google Scholar searches were completed to identify relevant publications that may have been missed during the electronic database search. No language limits were imposed at the time of screening of relevant articles. Randomized controlled trials, case-control studies, cohort studies, and case series were included. The investigators independently performed data extraction using a standard data extraction form to determine the eligibility for inclusion.
Treatment-emergent central sleep apnea
The following is an example of a PubMed/MEDLINE search strategy: (["Sleep Apnea, Central" (Mesh)] AND [(treatment-emergent) OR ("treatment emergent") OR (complex)]). All articles which discussed findings for initial and persistent central sleep apnea in patients with PAP treatment data were reviewed. Articles meeting the inclusion criteria were included in the systematic review.
Inclusion criteria were (1) all studies that included subjects with a new or established diagnosis of TECSA and (2) studies in which patients with TECSA were discretely evaluated at least at two distinct points in time and the data collected were made available. Exclusion criteria were (1) studies that did not define what constituted central sleep apnea, (2) studies that did not utilize PAP therapy to arrive at their determined rates of TECSA, and (3) studies that did not have at least two points in time with data available for evaluation.
Results
Based on the methodology, established inclusion, and exclusion criteria, five studies met criteria for detailed evaluation [ Figure 1 ]. [6] [7] [8] [9] [10] The demographic data and the PAP treatment data for these five studies are presented in Tables 1 and 2 All the studies used in-lab full-night titration to establish prevalence of TECSA, except Kuzniar et al., who used the titration portion of a split-night study, and Liu et al., who used a telemonitoring database (AirView; ResMed). The prevalence of TECSA in these five studies ranged 
Discussion
The typical course of TECSA appears variable [ Figure 2 ]. The majority of patients with TECSA show resolution of central apneas over a few weeks to months. Although most cases of TECSA resolve over time, about one-third of such patients convert to TPCSA related to PAP therapy. Our systematic review noted that 0.9%-3.2% of all patients treated with PAP therapy for OSA will exhibit TPCSA on a long-term basis [ Table 2 ]. They represent 14.3%-46.2% of TECSA patients, who continue to experience PAP therapy-related central sleep apnea over a protracted period after they were first diagnosed with TECSA. Javaheri et al. noted that the daily CPAP adherence tends to be lower in patients who eventually declare themselves as TPCSA on PAP-2 compared to patients who experience resolution of their TECSA.
The prevalence of TPCSA at 0.9%-3% in all patients with treated OSA may be an underrepresentation given some patients in the discussed studies were lost to follow-up after the first titration study. Cassel et al. reported a TPCSA prevalence of 3.2%, which was the highest of the five studies evaluating this phenomenon. Even this TPCSA prevalence figure could be an underestimation, as 28 out of the 82 patients with TECSA at PAP-1 were lost to follow-up and hence unavailable to undergo a PAP-2 study. Similarly, in the study by Dernaika et al.
which reported the TPCSA prevalence at 1.7%, it was noted that seven out of 21 patients with TECSA at PAP-1 were lost to follow-up and also unavailable for a PAP-2 study. Selective exclusion of patients with preexisting central sleep apnea from the titration study (as performed by Dernaika et al.) can also lead to underestimation of overall prevalence. Figure 2 ].
One plausible explanation for the dynamic nature of TECSA could be that the CO 2 reservoir and the apnea Referred to a "nonresponders" to CPAP with residual AHI >10 on PAP2 (individual breakdown of residual obstructive AHI and central AHI was not provided although median reported CAI in "nonresponders" in NREM was 12.5), # PAP1 denotes first titration study (or titration portion of the split-night study) that was used to determine prevalence of TECSA, ## PAP2 denotes second titration study done some weeks after PAP1 on patient with TECSA that was used to determine prevalence of TPCSA, *Percentage of TECSA patients who continue to have CPAP-related CSA (i.e., having TPCSA) on PAP2, **Percentage of OSA patients who continue to have CPAP related CSA (i.e., having TPCSA) on PAP2, [14] This variability in the apneic threshold could lead to emergence, persistence, or resolution of central apneas on PAP therapy depending on the degree of adaptation of chemoreceptors to the fluctuating CO 2 reservoir and the apneic threshold.
It appears that certain polysomnographic features specific to the individual patient with TECSA could be associated with higher chances of developing TPCSA independent of a time variable. Javaheri et al. noted that TECSA patients, who demonstrated TPCSA on subsequent PAP-2 titration when compared to those who showed resolution of TECSA, were more likely to have CAI of 5 or greater on their baseline study. The patients in the TPCSA group had higher baseline apnea-hypopnea index (AHI) and higher residual AHI at PAP-1 and PAP-2 when compared to those who showed resolution of TECSA (Javaheri et al.) . It is possible that TECSA patients with higher AHI and CAI at their baseline study as well as higher residual AHI, higher arousal index, lower total sleep time, and lower sleep efficiency at their titration studies predict higher chances of converting to TPCSA in the long run, but more robust data are required before such claims can be made conclusively.
Limitations
Our review has certain limitations. Only five studies were available for review limiting heterogeneity, sample size, and statistical power of the study. Three of the five studies were retrospective observational studies and had the same limitations as that of any retrospective study. The sample sizes for patients with TECSA undergoing PAP-2 study were generally smaller than those undergoing the PAP-1 study. The study by Liu et al. enrolling the largest number of OSA patients derived TECSA, D-TECSA, and TPCSA data based on CPAP machine download algorithms. Such data might not be consistent with central sleep apnea index determined by in-lab CPAP studies. Given the overwhelmingly large sample size of their study, their results to some extent might have skewed the final conclusions drawn from this systematic review. All studies reported a substantial number of patients with TECSA that were lost to follow-up between PAP-1 and PAP-2 which further limits the accuracy of estimation of TPCSA prevalence. Further, it is unknown if patients developed any new risk factors (heart failure, stroke, or use of opiate medications) between PAP-1 and PAP-2 studies that could have increased the estimated prevalence of TPCSA. Large-scale, prospective, well-designed studies will be required in the future to better understand the prevalence of TPCSA in patients diagnosed with TECSA during their first PAP titration study.
Conclusions
Overall, TECSA developed in 3.5%-19.8% of PAP-treated patients. About two-thirds of patients with TECSA on initial PAP exposure go on to experience complete resolution of central apneas over a period of few weeks to several months. However, a significant proportion demonstrating TECSA on initial PAP exposure may continue to exhibit TPCSA or persistence of central apneas on reevaluation. D-TECSA was observed in between 0.7% and 4.2% of patients undergoing PAP treatment after at least 1 month. In patients with TECSA, a higher AHI and CAI at their baseline study as well as a higher residual AHI at their titration study may be associated with increased likelihood of conversion to TPCSA in the long run. Given their unfavorable polysomnographic profile, patients with TPCSA may have poor adherence to PAP therapy and may need to be monitored closely. Future studies should consider enrolling higher number of patients with TECSA to better delineate the prevalence and risk factors associated with conversion to TPCSA.
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